iCell® Neurons Enable Alzheimer’s Disease Modeling
Research demonstrate potential use of iCell® Neurons in high throughput screening at GlaxoSmithKline.

Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer
GLPG1790 has high efficacy against triple-negative breast cancer.

A Molecular-Modeling Toolbox Aimed at Bridging the Gap Between Medicinal Chemistry and Computational Sciences
Researchers from the University of Basel have designed a versatile single-click tools to assist medicinal chemists in performing two routine modeling tasks.

Chemists Find Help from Nature in Fighting Cancer
Study of several dozen compounds based on a fungal chemical shows potent anti-tumor activity.

Gallo Center Scientists Identify Potential New Mechanism for Treating Problem Drinking
Researchers identified a potential new approach for reducing problem drinking: a new family of drugs with the ability to manipulate DNA structure without changing it.

€9m EU-project on Deep-Sea Organisms Started
The PharmaSea project will evaluate the potential of new bioactive compounds from marine organisms as novel drug leads or ingredients for nutrition or cosmetic applications.

Anti-cancer Drug Discovery and Development: Bcl-2 Family Small Molecule Inhibitors
In this article, researchers from The Pennsylvania University College of Medicine discuss the current status of Bcl-2 family small molecule inhibitors in preclinical and clinical development.

Chemists Devise Inexpensive, Benchtop Method for Marking and Selecting Cells
Chemists at The Scripps Research Institute have found an easier way to perform one of the most fundamental tasks in molecular biology.

Two MIT Professors Win Prestigious Wolf Prize
Michael Artin and Robert Langer honored for groundbreaking work in mathematics and chemistry.

Study Paves way to Design Drugs Aimed at Multiple Protein Targets at Once
Pharmaceutical chemists had suggested that the objective of a drug hitting multiple targets simultaneously is impossible and unlikely to succeed. This study shows how to efficiently and effectively make designer drugs that can do that.

Development of DIBENZOSUBERONES as Potent and Highly Selective p38 MAPK Inhibitors Stefan Laufer, Professor, Department Head, Eberhard-Karls-University Tuebingen, speaking at MedChem Europe 2009
Impedance-Based Measurement of GPCR Modulators in Drug Discovery – Characterization of Signalling Pathways in Recombinant and Non-Recombinant Cells John Gatfield, Senior Lab Head Molecular Biology, Actelion Pharmaceuticals Ltd, speaking at Screening Europe 2009
Advancing Drug Discovery in an Academic Setting Julie Frearson, Professor Biotechnology/Drug Discovery/Biological Chemistry and Molecular Pharmacology, University of Dundee, speaking at Screening Europe 2009
De Novo Molecular Design: A Powerful Strategy for the Discovery of New Potential Antimalarials and Antibacterials Colin Fishwick, Reader/ Director Organic Chemistry/Leeds Structure-Based Drug Design Group, University of Leeds School of Chemistry, speaking at MedChem Europe 2009
Intersecting Biological and Chemical Knowledge for Computational Toxicology Florian Nigsch, Research Associate, University of Cambridge, speaking at ADMET Europe 2009
CYP Poor Metaboliser Genotyping on the Agilent Bioanalyzer and Clinical Application Irina Piatkov, Senior Hospital Scientist, Diversity Health Institute, speaking at the Molecular Diagnostics World Congress 2009
Biomarkers as Expression Signatures: Combinatorial Problem Solved with Gene Networks Audrey Alexenko, Researcher, Stockholm Bioinformatics Centre, speaking at the Molecular Diagnostics World Congress 2009
Bioluminescent Cytochrome P450 Inhibition and Induction Assays: Comparisons to Conventional Methods Jim Cali, Senior Scientist, Promega, speaking at ADMET Europe 2009
In silico Prediction of ADMET Properties John Dearden, School of Pharmacy and Chemistry, Liverpool John Moores University, speaking as ADMET Europe 2009

<<	5 6 7 8 9 10 11	>>
Showing Results 71 - 80 of 121